Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price dropped 8.4% during mid-day trading on Wednesday . The stock traded as low as $7.12 and last traded at $7.16, with a volume of 95,731 shares trading hands. The stock had previously closed at $7.82.

KPTI has been the subject of several research analyst reports. Leerink Swann reiterated a “buy” rating and issued a $18.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, May 10th. Raymond James Financial Inc. initiated coverage on Karyopharm Therapeutics in a research note on Friday, May 27th. They issued an “outperform” rating and a $13.00 target price for the company. Jefferies Group cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 target price for the company. in a research note on Wednesday, June 1st. Wedbush reissued an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, June 10th. Finally, Robert W. Baird initiated coverage on Karyopharm Therapeutics in a research note on Monday, June 27th. They issued an “outperform” rating and a $16.00 target price for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $17.25.

The company’s market capitalization is $257.32 million. The company has a 50 day moving average price of $7.23 and a 200 day moving average price of $7.87.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.08. Equities analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.26) EPS for the current year.

In other Karyopharm Therapeutics news, major shareholder Ltd Chione sold 74,664 shares of the company’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $9.61, for a total transaction of $717,521.04. Following the completion of the sale, the insider now directly owns 8,713,878 shares in the company, valued at $83,740,367.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

An institutional investor recently raised its position in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC raised its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned approximately 0.25% of Karyopharm Therapeutics worth $1,167,000 as of its most recent SEC filing.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.